Improved Vaccination Responses and Optional Immunomodulating Therapy by Adjuvant Administration of COX-2 Inhibitor in HIV-infected Patients, 2015

The study is a prospective controlled study of HIV seropositive patients investigating whether an anti-inflammatory COX-2 inhibitor (etoricoxib) given respectively 2 and 24 weeks improves the ability of the immune response against T cell-dependent vaccines in in proportion to a control group. The project will also examine (i) effects on HIV-associated chronic immune activation, one pathogenetic unfortunate "driver" of HIV infection associated with rapid progression of HIV and cardiovascular risk; (ii) effect on HIV-specific immunity.